113 related articles for article (PubMed ID: 11391837)
1. Management of HIV infection in Nigeria with zalcitabine in combination with saquinavir mesylate: preliminary findings.
Akinsete I; Njoku OS; Okanny CC; Chukwuani CM; Akanmu AS;
West Afr J Med; 2000; 19(4):265-8. PubMed ID: 11391837
[TBL] [Abstract][Full Text] [Related]
2. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
3. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
[TBL] [Abstract][Full Text] [Related]
4. [The combination of saquinavir and ddC ensures longer survival].
Hoof T
Dtsch Med Wochenschr; 1996 Sep; 121(37):A30. PubMed ID: 8925721
[No Abstract] [Full Text] [Related]
5. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
[TBL] [Abstract][Full Text] [Related]
6. Saquinavir: major study shows survival benefit in treatment-naive patients.
James JS
AIDS Treat News; 1997 Jul; (No 274):6. PubMed ID: 11364463
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
8. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
9. Saquinavir combination results released.
AIDS Patient Care STDS; 1996 Aug; 10(4):261. PubMed ID: 11361600
[No Abstract] [Full Text] [Related]
10. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
Revicki DA; Moyle G; Stellbrink HJ; Barker C
AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
[TBL] [Abstract][Full Text] [Related]
11. Potent new AIDS drugs underscore promise of combination therapy.
AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Sangkitporn S; Shide L; Klinbuayaem V; Leenasirimakul P; Wirayutwatthana NA; Leechanachai P; Dettrairat S; Kunachiwa W; Thamlikitkul V
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):704-8. PubMed ID: 16124442
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus].
Soriano Vázquez V; Rodríguez-Rosado Martínez-Echevarría R; Jiménez-Nacher I; Valencia Ortega E; Moreno Celda V; González-Lahoz J
Rev Clin Esp; 1998 Sep; 198(9):634-5. PubMed ID: 9803794
[No Abstract] [Full Text] [Related]
14. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
[TBL] [Abstract][Full Text] [Related]
16. Saquinavir in the management of HIV infection.
Moyle G
Br J Hosp Med; 1997 Jun 4-17; 57(11):560-4. PubMed ID: 9307673
[TBL] [Abstract][Full Text] [Related]
17. A kinder, gentler ddC... for $7,200 a year.
GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362996
[TBL] [Abstract][Full Text] [Related]
18. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]